<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">43173</article-id><article-id pub-id-type="doi">10.7554/eLife.43173</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Scientific Correspondence</subject></subj-group><subj-group subj-group-type="heading"><subject>Stem Cells and Regenerative Medicine</subject></subj-group></article-categories><title-group><article-title>Comment on 'Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity'</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-92071"><name><surname>Pacifici</surname><given-names>Maurizio</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6854-4942</contrib-id><email>pacificim@email.chop.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-125323"><name><surname>Shore</surname><given-names>Eileen M</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-2609-6971</contrib-id><email>shore@pennmedicine.upenn.edu</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Translational Research Program in Pediatric Orthopaedics</institution><institution>The Children's Hospital of Philadelphia</institution><addr-line><named-content content-type="city">Philadelphia</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution content-type="dept">Department of Orthopaedic Surgery</institution><institution>University of Pennsylvania</institution><addr-line><named-content content-type="city">Philadelphia</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Rosen</surname><given-names>Clifford J</given-names></name><role>Reviewing Editor</role><aff><institution>Maine Medical Center Research Institute</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>McCarthy</surname><given-names>Mark I</given-names></name><role>Senior Editor</role><aff><institution>University of Oxford</institution><country>United Kingdom</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>30</day><month>01</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>8</volume><elocation-id>e43173</elocation-id><history><date date-type="received" iso-8601-date="2018-10-29"><day>29</day><month>10</month><year>2018</year></date><date date-type="accepted" iso-8601-date="2019-01-09"><day>09</day><month>01</month><year>2019</year></date></history><permissions><copyright-statement>© 2019, Pacifici and Shore</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Pacifici and Shore</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-43173-v1.pdf"/><related-article ext-link-type="doi" id="ra1" related-article-type="article-reference" xlink:href="10.7554/eLife.40814"/><related-article ext-link-type="doi" id="ra2" related-article-type="article-reference" xlink:href="10.7554/eLife.43928"/><abstract><object-id pub-id-type="doi">10.7554/eLife.43173.001</object-id><p>We are writing to communicate our concerns regarding the recently published study by Lees-Shepard et al. (2018).</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>rare skeleatal disorders</kwd><kwd>drug treatment</kwd><kwd>palovarotene</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>We are writing to communicate our concerns regarding the recently published study by Lees-Shepard et al. (2018).</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Lees-Shepard et al. reported that palovarotene (a retinoid agonist) had severe side effects on growth plate and limb joints in an Acvr1<sup>R206H</sup> knock-in mouse model of fibrodysplasia ossificans progressiva (FOP; <xref ref-type="bibr" rid="bib10">Lees-Shepard et al., 2018</xref>). We have a number of concerns about this publication. Lees-Shepard et al. write that “it is important for FOP therapeutics to exhibit an acceptable safety profile in juvenile patients”: however, they used a retinoid drug delivery method that is never used in the treatment of patients, thus undermining their goal. Moreover, the mouse model used does not sufficiently mimic FOP patients.</p></sec><sec id="s2" sec-type="discussion"><title>Discussion</title><sec id="s2-1"><title>Route of palovarotene administration</title><p>Palovarotene was originally designed for oral administration (<xref ref-type="bibr" rid="bib8">Hind and Stinchcombe, 2009</xref>), allowing for low and steady drug adsorption by the digestive system and an overall absorption efficiency of 50% to 65% of administered dose, typical of retinoids (<xref ref-type="bibr" rid="bib1">Blaner and Olson, 1994</xref>). Instead, Lees-Shepard et al. injected the drug intraperitoneally (IP) every day for 4 weeks. This IP route of administration is known to invariably cause a sharp and sudden increase in circulating drug levels, resulting in a higher and faster C<sub>max</sub> compared to oral delivery (<xref ref-type="bibr" rid="bib6">Eaton and Gilbert, 2013</xref>). Indeed, palovarotene C<sub>max</sub> levels were found to be about 6-fold higher after IP injection compared to oral administration in mice (Clementia Pharmaceuticals, internal data). Circulating retinoids are quickly taken up by tissues and cells (<xref ref-type="bibr" rid="bib5">Cullum and Zile, 1985</xref>), and cells accumulate retinoids in large amounts intracellularly (<xref ref-type="bibr" rid="bib9">Kurlandsky et al., 1995</xref>; <xref ref-type="bibr" rid="bib11">Randolph and Simon, 1997</xref>) where their action on cell function and phenotype can last hours to days (<xref ref-type="bibr" rid="bib3">Chen and Gudas, 1996</xref>). Thus, daily IP injections are expected to result in ever increasing and possibly confounding drug effects over time. Lees-Shepard et al. stated that they used “palovarotene doses….that correspond to approximate adult human equivalent doses of 3.6 mg and 7.2 mg” under testing in ongoing efficacy and safety study of palovarotene for the treatment of FOP being conducted by Clementia Pharmaceuticals (<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03312634.">https://clinicaltrials.gov/ct2/show/NCT03312634.</ext-link> This trial has recently entered phase 3). However, the IP administration changed the effective dose and undermined the goal of testing a clinically relevant treatment.</p></sec><sec id="s2-2"><title>FOP mouse model</title><p>Lees-Shepard et al. utilized a conditional mouse model in which the FOP causative gene was activated in Pdgfrα-expressing cells by mating floxed Acvr1<sup>R206H</sup> mice with Pdgfrα-Cre mice. Those cells were described as a subpopulation of progenitor cells particularly sensitive to effects of the mutation. This mouse model is at sharp variance with FOP patients in which the mutant ACVR1<sup>R206H</sup> gene characterizes the majority of, if not all, cells. Thus, data obtained with the Pdgfrα-Cre mouse model may be skewed by targeting a specific subpopulation of cells that could also be affected by wild-type cells, with the wild-type cells likely outnumbering the cells in the specific Acvr1<sup>R206H</sup> subpopulation and interacting with them. Thus, the model does not faithfully reproduce the overall genetic makeup and cell and tissue responses in FOP patients. While Lees-Shepard et al. observed that Pdgfrα+ cells contributed to heterotopic ossification (HO) in their model, it is not known whether this specific cell population is clinically relevant in FOP patients. Further, Lees-Shepard et al. presented no data showing that targeted Pdgfrα+ cells were present in the growing skeleton.</p></sec><sec id="s2-3"><title>Effects on growth plates and joints</title><p>These latter issues are particularly relevant to the severe effects on growth plates and joints reported by Lees-Shepard et al. Given that the Pdgfrα gene is not known to be expressed in chondrocytes (<xref ref-type="bibr" rid="bib7">Hamilton et al., 2003</xref>), it is nearly certain that growth plate and articular chondrocytes were not targeted by Pdgfrα-Cre and remained largely, if not totally, wild-type. Lees-Shepard et al. included no data to demonstrate that Pdgfrα-Cre had targeted growth plate and joint chondrocytes. Studies dating back decades have established that cartilage is sensitive to systemic retinoid levels (<xref ref-type="bibr" rid="bib13">Wolbach and Hegsted, 1953</xref>). In our studies (<xref ref-type="bibr" rid="bib2">Chakkalakal et al., 2016</xref>; <xref ref-type="bibr" rid="bib12">Shimono et al., 2011</xref>), we did observe a slight growth retardation of about 10% in control wild type mice after oral palovarotene administration, although their growth plates remained open and there were no obvious effects on their joints. Notably, there were no obvious growth retardation and growth plate effects after oral palovarotene administration in our Prrx1-Cre; Acvr1<sup>R206H</sup> mutant mice in which the entire limb mesenchymal cell population was targeted, including skeletal cells. The higher tolerance of mutant growth plates was likely due to higher basal levels of canonical BMP signaling activity. As we pointed out previously (<xref ref-type="bibr" rid="bib2">Chakkalakal et al., 2016</xref>), this provides support to the notion that palovarotene may be quite safe for – and well tolerated by – FOP patients, as supported by the announcement of Phase 2 Part B data from the ongoing efficacy and safety study being conducted by Clementia (<xref ref-type="bibr" rid="bib4">Clementia Pharmaceuticals, 2018</xref>).</p></sec><sec id="s2-4"><title>Conclusions</title><p>In sum, the severe side effects on growth plates and joints observed by Lees-Shepard et al. are likely the results of: (i) the route of drug administration; (ii) excessive palovarotene levels and effects likely caused by the daily IP administration; and (iii) reliance on a mouse model that does not mimic FOP patients, including apparent lack of mutation expression in cartilage. We strongly recommend that data and conclusions in that study should be considered and interpreted with caution with regard to drug effects and action in skeletal tissues and for relevance to ongoing clinical studies.</p></sec></sec></body><back><sec id="s4" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>MP is a consultant for Clementia Pharmaceuticals</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Formal analysis</p></fn></fn-group></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Blaner</surname> <given-names>WS</given-names></name><name><surname>Olson</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="1994">1994</year><chapter-title>Retinol and retinoic acid metabolism</chapter-title><person-group person-group-type="editor"><name><surname>Sporn</surname> <given-names>MB</given-names></name><name><surname>Roberts</surname> <given-names>AB</given-names></name><name><surname>Goodman</surname> <given-names>DS</given-names></name></person-group><source>The Retinoids: Biology, Chemistry, and Medicine</source><edition>Second Edition</edition><publisher-loc>New York</publisher-loc><publisher-name>Raven Press</publisher-name><fpage>229</fpage><lpage>255</lpage></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chakkalakal</surname> <given-names>SA</given-names></name><name><surname>Uchibe</surname> <given-names>K</given-names></name><name><surname>Convente</surname> <given-names>MR</given-names></name><name><surname>Zhang</surname> <given-names>D</given-names></name><name><surname>Economides</surname> <given-names>AN</given-names></name><name><surname>Kaplan</surname> <given-names>FS</given-names></name><name><surname>Pacifici</surname> <given-names>M</given-names></name><name><surname>Iwamoto</surname> <given-names>M</given-names></name><name><surname>Shore</surname> <given-names>EM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Palovarotene inhibits heterotopic ossification and maintains limb mobility and growth in mice with the <italic>human ACVR1</italic><sup>(R206H</sup>) Fibrodysplasia ossificans progressiva (FOP) mutation</article-title><source>Journal of Bone and Mineral Research</source><volume>31</volume><fpage>1666</fpage><lpage>1675</lpage><pub-id pub-id-type="doi">10.1002/jbmr.2820</pub-id><pub-id pub-id-type="pmid">26896819</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>AC</given-names></name><name><surname>Gudas</surname> <given-names>LJ</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>An analysis of retinoic acid-induced gene expression and metabolism in AB1 embryonic stem cells</article-title><source>Journal of Biological Chemistry</source><volume>271</volume><fpage>14971</fpage><lpage>14980</lpage><pub-id pub-id-type="doi">10.1074/jbc.271.25.14971</pub-id><pub-id pub-id-type="pmid">8663043</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="web"><person-group person-group-type="author"><collab>Clementia Pharmaceuticals</collab></person-group><year iso-8601-date="2018">2018</year><article-title>Clementia announces updated phase 2 part B data on palovarotene for FOP</article-title><source>Globe Newswire</source><ext-link ext-link-type="uri" xlink:href="https://globenewswire.com/news-release/2018/09/26/1576476/0/en/Clementia-Announces-Updated-Phase-2-Part-B-Data-on-Palovarotene-for-FOP.html">https://globenewswire.com/news-release/2018/09/26/1576476/0/en/Clementia-Announces-Updated-Phase-2-Part-B-Data-on-Palovarotene-for-FOP.html</ext-link><date-in-citation iso-8601-date="2018-12-09">December 9, 2018</date-in-citation></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cullum</surname> <given-names>ME</given-names></name><name><surname>Zile</surname> <given-names>MH</given-names></name></person-group><year iso-8601-date="1985">1985</year><article-title>Metabolism of all-trans-retinoic acid and all-trans-retinyl acetate. Demonstration of common physiological metabolites in rat small intestinal mucosa and circulation</article-title><source>The Journal of Biological Chemistry</source><volume>260</volume><fpage>10590</fpage><lpage>10596</lpage><pub-id pub-id-type="pmid">4030759</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Eaton</surname> <given-names>DL</given-names></name><name><surname>Gilbert</surname> <given-names>SG</given-names></name></person-group><year iso-8601-date="2013">2013</year><chapter-title>Principles of toxicology</chapter-title><person-group person-group-type="editor"><name><surname>Klaassen</surname> <given-names>CD</given-names></name></person-group><source>Casarett and Doull's Toxicology: The Basic Science of Poisons</source><edition>Eighth Edition</edition><publisher-loc>London</publisher-loc><publisher-name>McGraw-Hill</publisher-name></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamilton</surname> <given-names>TG</given-names></name><name><surname>Klinghoffer</surname> <given-names>RA</given-names></name><name><surname>Corrin</surname> <given-names>PD</given-names></name><name><surname>Soriano</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Evolutionary divergence of platelet-derived growth factor alpha receptor signaling mechanisms</article-title><source>Molecular and Cellular Biology</source><volume>23</volume><fpage>4013</fpage><lpage>4025</lpage><pub-id pub-id-type="doi">10.1128/MCB.23.11.4013-4025.2003</pub-id><pub-id pub-id-type="pmid">12748302</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hind</surname> <given-names>M</given-names></name><name><surname>Stinchcombe</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Palovarotene, a novel retinoic acid receptor gamma agonist for the treatment of emphysema</article-title><source>Current Opinion in Investigational Drugs</source><volume>10</volume><fpage>1243</fpage><lpage>1250</lpage><pub-id pub-id-type="pmid">19876792</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurlandsky</surname> <given-names>SB</given-names></name><name><surname>Gamble</surname> <given-names>MV</given-names></name><name><surname>Ramakrishnan</surname> <given-names>R</given-names></name><name><surname>Blaner</surname> <given-names>WS</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Plasma delivery of retinoic acid to tissues in the rat</article-title><source>Journal of Biological Chemistry</source><volume>270</volume><fpage>17850</fpage><lpage>17857</lpage><pub-id pub-id-type="doi">10.1074/jbc.270.30.17850</pub-id><pub-id pub-id-type="pmid">7629087</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lees-Shepard</surname> <given-names>JB</given-names></name><name><surname>Nicholas</surname> <given-names>SE</given-names></name><name><surname>Stoessel</surname> <given-names>SJ</given-names></name><name><surname>Devarakonda</surname> <given-names>PM</given-names></name><name><surname>Schneider</surname> <given-names>MJ</given-names></name><name><surname>Yamamoto</surname> <given-names>M</given-names></name><name><surname>Goldhamer</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity</article-title><source>eLife</source><volume>7</volume><elocation-id>e40814</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.40814</pub-id><pub-id pub-id-type="pmid">30226468</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Randolph</surname> <given-names>RK</given-names></name><name><surname>Simon</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Metabolism of all-<italic>trans</italic>-retinoic acid by cultured human epidermal keratinocytes</article-title><source>Journal of Lipid Research</source><volume>38</volume><fpage>1374</fpage><lpage>1383</lpage><pub-id pub-id-type="pmid">9254063</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimono</surname> <given-names>K</given-names></name><name><surname>Tung</surname> <given-names>WE</given-names></name><name><surname>Macolino</surname> <given-names>C</given-names></name><name><surname>Chi</surname> <given-names>AH</given-names></name><name><surname>Didizian</surname> <given-names>JH</given-names></name><name><surname>Mundy</surname> <given-names>C</given-names></name><name><surname>Chandraratna</surname> <given-names>RA</given-names></name><name><surname>Mishina</surname> <given-names>Y</given-names></name><name><surname>Enomoto-Iwamoto</surname> <given-names>M</given-names></name><name><surname>Pacifici</surname> <given-names>M</given-names></name><name><surname>Iwamoto</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-γ agonists</article-title><source>Nature Medicine</source><volume>17</volume><fpage>454</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1038/nm.2334</pub-id><pub-id pub-id-type="pmid">21460849</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolbach</surname> <given-names>SB</given-names></name><name><surname>Hegsted</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="1953">1953</year><article-title>Hypervitaminosis A in young ducks: The epiphyseal cartilage</article-title><source>Archives of Pathology</source><volume>55</volume><fpage>47</fpage><lpage>54</lpage></element-citation></ref></ref-list></back></article>